Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

Preliminary data from an ongoing Phase 2 trial evaluating satraplatin plus Taxol(R) (paclitaxel) in the first-line treatment of patients with advanced non-small cell lung cancer were also published in the ASCO educational book (Shipley, D. et al. Phase II trial of satraplatin and paclitaxel in the first-line treatment of advanced non-small cell lung cancer). Data from 24 patients were available for analysis; a total of approximately 40 patients are expected to be enrolled in the study. This preliminary analysis showed that satraplatin plus Taxol appears to have activity in this treatment setting. In an effort to reduce myelosuppression in the study, the satraplatin dose has been lowered to 70 mg/m2 from 80 mg/m2. The study continues to enroll and follow patients.

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration. Satraplatin is an oral compound that clinical trial patients are able to take at home. Satraplatin is not currently approved by the FDA in the United States, by the EMEA in the European Union or any other regulatory authority and no conclusions can or should be drawn regarding its safety and efficacy.

A Phase 3 registrational trial, called SPARC, is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone- refractory prostate cancer whose prior chemotherapy has failed. Data from the trial on progression-free survival and on safety have been presented at recent medical conferences.

GPC Biotech has a co-development and license agreement with Pharmion GmbH, a wholly owned subsidiary of Pharmion Corporation, under which Pharmion has been granted exclusive commercialization rights to satraplatin for Europe and certain other territories.
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "China Orthopedic Instrument Industry Report, 2014-2017" report ... aging population and rising proportion of reimbursement for medical ... effectively released, with its scale presenting a CAGR of ... products are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... According to a new ... type (SFE, Cold Pressed, Organic Solvent, & Others), and ... Fragrance, & Others) - Global Trends & Forecast ... the Amaranth Seed Oil Market with an analysis ... of value. The Amaranth Seed Oil Market size ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
... Decision Resources, one of the world,s leading research and ... the launch of novel therapies for the treatment of ... telaprevir and Merck,s boceprevir, will precipitate several changes in ... C Virus , surveyed physicians plan to initiate treatment ...
... KERX ) today announced that Ron Bentsur, the ... Securities Healthcare Conference, being held at the New York Palace ... to take place tomorrow, Tuesday, September 28, 2010, at 1:00 ... presentation will be accessible from the Investor Information page of ...
Cached Medicine Technology:Launch of Novel Agents for the Treatment of Hepatitis C Virus Will Precipitate Treatment of At Least Half of 'Warehoused' Patients 2Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference 2
(Date:9/2/2014)... At the 50th Annual Mr. Olympia Fitness ... exhibitor at the Las Vegas Convention Center South Hall, ... Booth #374 Sept 19th and 20th 10am-5PM. , ... exercise, diet and supplementation. They pride themselves on creating ... for all Prosupps customers to reach their personal health ...
(Date:9/2/2014)... Tuesday 2 September 2014: Digoxin may increase the ... by approximately 20%, according to results from the ROCKET ... Manesh Patel, director of interventional cardiology and catheterisation labs ... US. The findings suggest that caution may be needed ... studies are needed to confirm the observations. , Dr ...
(Date:9/2/2014)... 02, 2014 Aeroflow Healthcare, an industry ... Southeast, announced the opening of its new office to ... is: 310 Business Parkway, Suite D, Greer, SC 29651. ... patients with a more convenient location in the Greenville ... Healthcare and the physicians, hospitals and patients we serve, ...
(Date:9/2/2014)... Productive Dentist Academy, a dental ... State, has been named to Inc. Magazine’s 5000 list ... the third year in a row it has obtained ... astonishing 63 percent growth rate and increased revenues from ... increased its number of employees from eight to 25. ...
(Date:9/2/2014)... hosting is a great choice for webmasters to build ... suppliers and announced that Arvixe, Bluehost and JustHost are ... hard to find a good fast hosting supplier. Actually, ... uptime, server speed and customer support. People can get ... of Top10BestSEOHosting.com says. , Arvixe has a world-class data ...
Breaking Medicine News(10 mins):Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Dental Management Company Named to Fastest-Growing List Again 2Health News:Dental Management Company Named to Fastest-Growing List Again 3Health News:Top10BestSEOHosting.com Recommends Fast Web Hosting Suppliers 2
... patients undergoing team-based care do not save more ... other patients, but they are healthier, according to ... substantial financial burden on patients, payers and employers," ... administration, Penn State, and lead author of the ...
... issue of the Journal of Leukocyte Biology ... efficacy of the current tuberculosis vaccine. Specifically, a team ... I interferon, in which it improves the ability of ... bacterium known to cause tuberculosis. The researchers speculate that ...
... as an ingredient in sunscreen, researchers say , , THURSDAY, Feb. ... might offer some protection from skin cancer, and new research ... to be the mechanism by which caffeine is associated with ... associate professor of dermatology at the University of Washington in ...
... Feb. 26 The following release was issued today ... federal vaccine court ruled against three families claiming vaccines ... writers Robert F Kennedy, JR and David Kirby reported ... who regressed into autism following the MMR vaccine. Last ...
... 2010 Budget Must Complement Stimulus Policy Objectives, Not Undermine ... a new bipartisan letter from four U.S. House lawmakers ... eldercare funding, the Coalition to Protect Senior Care (CPSC) ... Reinvestment Act (ARRA) will help strengthen the nation,s long ...
... to save cancer patients, lives can also destroy their ... oncofertility has advanced the ability of doctors to preserve ... are diagnosed with cancer. Yet, many oncologists aren,t familiar ... A leading oncofertility researcher and a breast surgical oncologist ...
Cached Medicine News:Health News:Team-based diabetes care fetches more value for dollar 2Health News:New discovery gives tuberculosis vaccine a shot in the arm 2Health News:Caffeine May Offer Some Skin Cancer Protection 2Health News:Caffeine May Offer Some Skin Cancer Protection 3Health News:On the Heels of Court Ruling Denying Autism-Vaccine Link, U.S. Federal Court Declares MMR Vaccine Caused Autism in a Young Boy 2Health News:Coalition to Protect Senior Care Praises Bipartisan House Effort to Protect Seniors' Nursing Home Care, LTC Workforce 2Health News:New tool guides doctors to save cancer patients' fertility 2Health News:New tool guides doctors to save cancer patients' fertility 3
... Super-Sect is a single-use device that ... minimal thermal spread and vapor sealing ... It can be used for resection ... tumor. It is also an excellent ...
... minimally invasive treatment for prostate and renal ... use, SeedNet provides optimum accuracy, efficiency and ... is the new generation in cryotherapy for ... SeedNet system, produce iceballs of extreme sub-zero ...
Thermal Cautery, Reusable Base Unit. Burns at approximately 1200C (2200 F), non-sterile base unit with 1 non-sterile tip, 1 set single-use batteries. The two (2) AA batteries are replaceable (alkalin...
... 2201 is ideal for applications such ... of heat. , ,The autoclavable handpiece ... of reusable thermal cautery electrodes, allowing ... to perform a wide variety of ...
Medicine Products: